Premium
Gut microbiota profiles and the role of anti‐CdtB and anti‐vinculin antibodies in patients with functional gastrointestinal disorders (FGID)
Author(s) -
Vasapolli Riccardo,
Schulz Christian,
Schweden Melanie,
Casèn Christina,
Kirubakaran Graceline Tina,
Kirste Katrine Hånes,
Macke Lukas,
Link Alexander,
Schütte Kerstin,
Malfertheiner Peter
Publication year - 2021
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/eci.13666
Subject(s) - dysbiosis , medicine , vinculin , antibody , microbiome , gastroenterology , immunology , irritable bowel syndrome , gut flora , biology , bioinformatics , biochemistry , phosphorylation , focal adhesion
Background Distinct faecal microbiota profiles are reported to be associated with various subtypes of IBS. Circulating antibodies to cytolethal distending toxin B (CdtB) and vinculin are proposed as biomarkers to identify post‐infectious IBS. The aim of our study was to analyse serum levels of anti‐CdtB and anti‐vinculin antibodies in patients with different functional gastrointestinal disorders (FGID) and their correlation with the composition of faecal microbiome. Methods The study cohort comprised 65 prospectively recruited individuals: 15 with diarrhoea‐type‐IBS (IBS‐D), 13 with constipation‐type‐IBS (IBS‐C), 15 with functional dyspepsia (FD) and 22 healthy controls. FGID subgroups were defined according to Rome III criteria. Serum levels of anti‐CdtB and anti‐vinculin antibodies were measured by ELISA. Faecal microbiome composition analysis and assessment of dysbiosis were performed by GA‐map® Dysbiosis Test. Results Positivity rate either for anti‐CdtB or anti‐vinculin antibodies was higher in the IBS‐C group (76.9%) compared to IBS‐D (40.0%), FD (60%) and healthy (63.6%) groups. Dysbiosis was more frequent in subjects positive for anti‐CdtB antibodies and in IBS‐C patients, who showed an increased amount of opportunistic/pro‐inflammatory bacteria and reduced gut protective bacteria. IBS‐C patients showed a high inter‐individual variation of bacterial communities compared to other FGID subgroups and healthy individuals, whereas microbial profiles of patients with IBS‐D and FD were overlapping with those of healthy controls. No bacteria markers showed significant differences between FGID subgroups and healthy controls. Conclusion Neither anti‐CdtB/anti‐vinculin antibodies nor faecal microbial profiles allowed to discriminate between specific FGID subgroups. Dysbiosis was more frequent in patients presenting with anti‐CdtB antibodies and in IBS‐C patients.